Puma Biotechnology Inc (PBYI)

78.05
3.10 4.14
NASDAQ : Health Care
Prev Close 74.95
Open 75.95
Day Low/High 74.65 / 80.00
52 Wk Low/High 27.64 / 75.10
Volume 5.69M
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 36.97M
Market Cap 2.14B
EPS -8.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology Receives FDA Advisory Committee Support For Neratinib

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that the U.

This Market is Now Overbought; Waiting for Another Pullback

This Market is Now Overbought; Waiting for Another Pullback

Despite the good action in the indices, I'm not putting much money to work.

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.

Puma Biotechnology Announces Posting Of FDA Oncologic Drugs Advisory Committee Briefing Documents For Neratinib Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the U.

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2017 ASCO Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

Puma Biotechnology Reports First Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017.

Puma Biotechnology To Present At Bank Of America Merrill Lynch 2017 Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.

PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc.

A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories

A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories

The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

Puma Biotechnology Announces FDA Advisory Committee To Review Neratinib For The Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.

Figure 1: Treatment-Emergent Diarrhea, CONTROL Vs ExteNET (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

A Waterfall Plot Showing "% Change In Size Of Target Lesions" From Puma Biotechnology's FB-10 Trial In HER2-positive Metastatic Breast Cancer Is Attached. (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the...

Puma Biotechnology Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

Puma Biotechnology Launches Expanded Access Program For PB272 (Neratinib) For U.S. Patients With HER2-Positive Breast Cancer Or HER2-Mutated Cancers

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to patients with...

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

These Stocks Are Trending Up With Monster Volume

These Stocks Are Trending Up With Monster Volume

Let's take a look at several stocks that are experiencing unusual volume activity.

7 Stocks Trending Up With Monster Volume

7 Stocks Trending Up With Monster Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.